E2086
/ Eisai
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
February 26, 2025
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Eisai Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Narcolepsy • Sleep Disorder
January 16, 2025
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed
Trial completion
August 27, 2024
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
August 20, 2024
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Narcolepsy • Sleep Disorder
July 01, 2024
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial
June 17, 2024
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial • Narcolepsy • Sleep Disorder
April 19, 2024
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=53 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed
Trial completion
August 28, 2023
E2086, a novel selective Orexin-2 receptor agonist
(WSS 2023)
- No abstract available
March 10, 2023
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
February 27, 2023
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial
1 to 10
Of
10
Go to page
1